Aktienanalyse zu IRIDEX Corp (IRIX)IRIXIRIDEX Corp

IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

IRIDEX Corp is not a good buy right now due to its current price of $0.6757, which is significantly below its 52-week high of $1.65, indicating a 59.0% decline. Additionally, the RSI is at 23.049, suggesting the stock is oversold, but the forward P/E ratio of 769.23 indicates extremely high valuation expectations that are unlikely to be met given the company's ongoing losses.

1 analysts cover IRIX: 1 rate it Buy, 0 Hold and 0 Sell.